KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Issued (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Shares Issued data on record, last reported at $503.5 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 453.91% year-over-year to $503.5 million; the TTM value through Dec 2025 reached $635.9 million, down 56.6%, while the annual FY2025 figure was $635.9 million, 56.6% down from the prior year.
  • Shares Issued reached $503.5 million in Q4 2025 per REGN's latest filing, up from $40.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $682.1 million in Q1 2024 and bottomed at $31.5 million in Q2 2025.
  • Average Shares Issued over 5 years is $286.0 million, with a median of $301.0 million recorded in 2023.
  • The widest YoY moves for Shares Issued: up 453.91% in 2025, down 92.8% in 2025.
  • A 5-year view of Shares Issued shows it stood at $95.0 million in 2021, then soared by 292.21% to $372.6 million in 2022, then fell by 19.22% to $301.0 million in 2023, then tumbled by 69.8% to $90.9 million in 2024, then surged by 453.91% to $503.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $503.5 million in Q4 2025, $40.3 million in Q3 2025, and $31.5 million in Q2 2025.